Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Aspirin 650mg Oral Capsule

A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.

DRUG

Acetaminophen Tablet 650mg

A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.

OTHER

Placebo

A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Columbia University

OTHER

NCT03824938 - Aspirin for Exercise in Multiple Sclerosis (ASPIRE) | Biotech Hunter | Biotech Hunter